Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).

Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF Jr.

Cancer. 2012 Jan 15;118(2):571-8. doi: 10.1002/cncr.26270. Epub 2011 Jun 28.

2.

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI; Alliance for Clinical Trials In Oncology.

Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.

3.

CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Tsavaris N, Kosmas C, Papadoniou N, Kopterides P, Tsigritis K, Dokou A, Sarantonis J, Skopelitis H, Tzivras M, Gennatas K, Polyzos A, Papastratis G, Karatzas G, Papalambros A.

J Chemother. 2009 Dec;21(6):673-80. Erratum in: J Chemother. 2010 Feb;22(1):72. Kopteridis, P [corrected to Kopterides, P].

PMID:
20071292
4.

Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.

Karabulut S, Afsar ÇU, Karabulut M, Alış H, Kılıc L, Çikot M, Yasasever CT, Aykan NF.

J Gastrointest Cancer. 2016 Mar;47(1):47-54. doi: 10.1007/s12029-015-9787-z.

PMID:
26637231
5.

Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.

Han SX, Zhou X, Sui X, He CC, Cai MJ, Ma JL, Zhang YY, Zhou CY, Ma CX, Varela-Ramirez A, Zhu Q.

Oncotarget. 2015 Aug 14;6(23):19907-17.

6.

Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.

Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM, Bigbee WL.

J Proteome Res. 2010 Dec 3;9(12):6440-9. doi: 10.1021/pr100696n. Epub 2010 Oct 28.

7.

Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.

Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, Anderson MA, Shedden KA, Ruffin MT, Lubman DM.

J Proteome Res. 2014 Apr 4;13(4):1873-84. doi: 10.1021/pr400967x. Epub 2014 Mar 10.

8.

Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery.

Yu KH, Barry CG, Austin D, Busch CM, Sangar V, Rustgi AK, Blair IA.

J Proteome Res. 2009 Mar;8(3):1565-76. doi: 10.1021/pr800904z.

9.

Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2605-10. doi: 10.1158/1055-9965.EPI-10-0178. Epub 2010 Aug 20.

10.

Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma.

Kobayashi S, Ueno M, Irie K, Goda Y, Aoyama T, Morinaga S, Ohkawa S, Morimoto M.

Pancreatology. 2015 Sep-Oct;15(5):525-530. doi: 10.1016/j.pan.2015.07.003. Epub 2015 Jul 29.

PMID:
26255025
11.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE.

J Clin Oncol. 2005 Nov 1;23(31):8033-40.

PMID:
16258101
12.

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R.

Cancer. 2012 Mar 1;118(5):1422-8. doi: 10.1002/cncr.26413. Epub 2011 Aug 5.

13.

Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues.

Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, Ishida K, Minowa T, Hanagata N, Ohtsuka H, Katayose Y, Egawa S, Nishimura T, Unno M.

Int J Cancer. 2013 Mar 15;132(6):1368-82. doi: 10.1002/ijc.27797. Epub 2012 Sep 14.

14.

Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.

Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem JL.

Oncology. 2007;73(1-2):41-51. doi: 10.1159/000120627. Epub 2008 Mar 11.

PMID:
18334830
15.

Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.

Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.

Mol Cell Proteomics. 2010 Apr;9(4):695-704. doi: 10.1074/mcp.M900234-MCP200. Epub 2010 Jan 8.

16.

Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.

Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L, Zhao Y.

Pancreatology. 2013 May-Jun;13(3):290-7. doi: 10.1016/j.pan.2013.03.010. Epub 2013 Mar 15.

PMID:
23719603
17.

Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.

Qi Q, Geng Y, Sun M, Chen H, Wang P, Chen Z.

Pancreas. 2015 Aug;44(6):977-82. doi: 10.1097/MPA.0000000000000353.

PMID:
25931258
18.

Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.

Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, Park JY.

Yonsei Med J. 2013 May 1;54(3):643-9. doi: 10.3349/ymj.2013.54.3.643.

19.

High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.

Xie H, Jiang W, Xiao SY, Liu X.

J Histochem Cytochem. 2013 Feb;61(2):148-55. doi: 10.1369/0022155412468137. Epub 2012 Nov 4.

20.

Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.

Qi Q, Geng Y, Sun M, Wang P, Chen Z.

Pancreatology. 2015 Mar-Apr;15(2):145-50. doi: 10.1016/j.pan.2014.12.004. Epub 2015 Jan 10.

PMID:
25641673

Supplemental Content

Support Center